News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

21,106 signal articles · 531 in last 24h · 103,813 total before filter · latest 22m ago

531last 24h

2508last 7d

477● bullish (7d)

255● bearish (7d)

197publishers

All Macro231 Earnings1482 M&A143 Regulatory15 Product5 Analyst29

✕ clear all filtersticker: TEMSentiment:bullish neutral bearish ✓ showing all (incl. clickbait)

Motley Fool9d agobullish

Cathie Wood's Ark Bought $21.3 Million of SpaceX Stock as Shares Fell 45% From Their Record High. Wall Street's Median Price Target Is $243.81, 111.5% Above the Current Close.

Cathie Wood's investment fund is heavily invested in SpaceX stock.

CRSP NVDA SPCX TEM TSLA

Insider Monkey64d agobullish

H.C. Wainwright Maintains Buy Rating on Tempus AI (TEM) Following Strong Revenue Growth

Tempus AI, Inc. (NASDAQ:TEM) ranks among the best short squeeze stocks to invest in. Following the company’s first-quarter results, H.C. Wainwright reduced its price target for Tempus AI, Inc. (NASDAQ:TEM) to $64 from $95 while retaining a Buy rating on the company’s shares. Tempus AI, Inc. (NASDAQ:TEM) posted total revenue of $348.1 million in Q1, […]

GILD MRK TEM

Simply Wall St.65d agobullish

Tempus AI (TEM) Is Up 9.3% After New FDA-Cleared CDx And AI Oncology Platform Upgrades

In recent days, Tempus AI announced a string of oncology-focused product advances, including FDA approval of its xT CDx tumor-only sequencing assay, major upgrades to its AI-enabled Next and Hub platforms, and new tools like Preview, Lens, and the ArteraAI Prostate Test (mHSPC) that deepen its role in precision cancer care. Taken together, these moves highlight Tempus AI’s effort to turn its multimodal data and foundation models into end-to-end clinical and biopharma solutions, from faster...

TEM